There are no reported clinical trial data on the effectiveness of probucol treatment in slowing the progression of atherosclerosis. Such a trial is now in progress in Sweden, using femoral angiography to assess progression or regression of lesions.38 Unfortunately, the design of this study is such that it will probably not answer the question of whether the antioxidant effect of probucol contributes to any observed beneficial effect. Only subjects who showed at least a 10% further drop in cholesterol level when started on probucol were eligible for randomization. Consequently, there will be at least a 10% difference in cholesterol level between the probucol-treated group and the group not receiving probucol. Therefore, even if there is an apparent benefit in terms of progression, it will not be possible to ascribe that benefit to the cholesterol-lowering effect, to the antioxidant effect, or to both. Ultimately, if one wants to specifically assess the antioxidant property of probucol as it relates to atherogenesis, a design analogous to that used by Carew, Schwenke and Steinberg17 in studies of Watanabe rabbits will have to be used.
There is a sizable literature on the use of antioxidants in the clinic, but almost without exception these papers are anecdotal or do not have the kind of careful, double-blind design that is needed to firmly establish the effectiveness of a therapy. The first double-blind study is in progress (the Harvard Physicians' Heart Study), and a preliminary report indicates a significant protective effect with a3-carotene supplementation. 39 Also worthy of note is a growing body of epidemiologic evidence showing a negative correlation between levels of antioxidants and risk of coronary heart disease. 40 How should we assess the degree of protection afforded even in the in vitro systems? These systems are crudely defined at the moment and they may or may not reflect appropriately the conditions in the wall of the artery, which are the conditions that really matter. For example, a number of investigators are using the lag time during oxidation of LDL in vitro as an indicator of the extent of antioxidant protection afforded. Is that the only relevant parameter? What about the rate of and the extent of diene conjugation? The latter can be strongly influenced by the fatty acid composition of the LDL. Recent studies by Parthasarathy43 have shown that feeding rabbits a diet highly enriched in oleic acid leads to the formation of LDL molecules that are remarkably resistant to oxidative modification, not because of a difference in antioxidant content but because of the difference in fatty acid composition.
Another example will illustrate how far we are from fully understanding this system. We are not even sure whether the oxidation of LDL is due to the release of superoxide anion from the cells or the action of cellular lipoxygenases or some combination of the two. [44] [45] [46] [47] The in vitro systems we use have the LDL in free solution and depend upon the presence of transition metal ions in the medium. In the subendothelial space the oxidation may occur in a sequestered "micro-environment" and may be based on quite different mechanisms.
Another example will illustrate the gap in our knowledge. We do not know whether the generation of cytotoxic fatty acid degradation products in LDL is more important in the atherogenic process perhaps than the conversion of the LDL to a form that can generate foam cells. If it is, then we should be measuring that property of oxidized LDL rather than simply measuring thiobarbituric acid-reactive substances or rates of uptake of modified LDL by macrophages.
Another issue that needs to be given careful thought is the age of subjects to be chosen for a clinical trial. The oxidation modification hypothesis originally was concerned primarily with the conversion of LDL to a form recognized by the scavenger receptor(s). If this were the major difference between native LDL and oxidized LDL, then oxidative modification might be relevant only to the generation of the fatty streak lesions and not necessarily relevant to the evolution of that lesion to the more complicated and more clinically significant lesions. On the other hand, there is considerable evidence that the fatty streak is the precursor of most of the advanced, clinically significant lesions, both in animals and in man. 48 
Summary
Oxidative modification of LDL may very well play a significant role in atherogenesis. At some point this hypothesis will have to be tested critically in a clinical setting. At this time, however, our knowledge is incomplete, and it is not really possible to make fully informed decisions about how such a trial should be conducted: that is, with which antioxidant, in which population, for how long, etc. It would be best to await results of further basic studies in animal models and the results of pilot studies in humans before launching what will necessarily be a very expensive and timeconsuming project. It would be especially unfortunate if such a study were conducted in a less than optimal manner and yielded a negative or an inconclusive result. That might make it more difficult to obtain the necessary enthusiasm and financial support at a later time for a more appropriate clinical trial. 
